Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Modalis Therapeutics Corporation ( (JP:4883) ) has issued an announcement.
Modalis Therapeutics Corporation reported non-operating income of 14 million yen in foreign exchange gains for the three months ended March 31, 2026, driven primarily by the revaluation of its foreign currency-denominated assets and liabilities amid exchange rate fluctuations. This foreign exchange income provides a modest boost to the company’s quarterly earnings and highlights its exposure to currency movements, an ongoing factor that investors and other stakeholders must consider when assessing its financial performance.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a biotechnology company listed on the Tokyo Stock Exchange that focuses on developing therapeutic technologies, with operations that involve holding foreign currency-denominated assets and liabilities. The company’s financial results are therefore sensitive to movements in foreign exchange rates, which can generate non-operating gains or losses depending on currency fluctuations.
Average Trading Volume: 3,062,451
Technical Sentiment Signal: Sell
Current Market Cap: Yen6.44B
For an in-depth examination of 4883 stock, go to TipRanks’ Overview page.